WT1 and acute myeloid leukemia: A more promising approach has been the development of cell‐based vaccines comprising autologous monocyte‐derived DCs (moDCs) loaded in vitro with WT1 mRNA, which have been shown to prevent and/or delay relapse after chemotherapy and improve overall survival in patients with high‐risk AML.14, 15